{"id":{"repo_id":"wfu","oai_identifier":"oai:wakespace.lib.wfu.edu:10339/86347"},"canonical_url":"https://search.dev.ndltd.org/etd/wfu/oai:wakespace.lib.wfu.edu:10339/86347","repository":{"repo_id":"wfu","name":"Wake Forest University","base_url":"https://wakespace.lib.wfu.edu/oai/request"},"display":{"title":"Evaluation of genetic variants for Type 2 diabetes associated kidney disease in African Americans","abstract":"End-stage kidney disease (ESKD) is a significant public health problem in the U.S., disproportionately affecting African Americans (AAs; 1,003 per million/year) at 3.3-fold higher incidence rate than European Americans (301 per million/year), and 2-fold higher than Native Americans (499 per million/year) in 2014. Diabetic kidney disease (DKD), primarily attributed to type 2 diabetes (T2D), including ESKD and advanced chronic kidney disease (CKD) accounts for over 40% of all ESKD cases. Observation of familial aggregation in epidemiologic studies suggests that genetic factors may contribute to the risk of DKD. While apolipoprotein L1 gene (APOL1) G1 and G2 alleles explain approximately 70% of the disparity in non-diabetic ESKD in AAs, they fail to account for the excess risk of T2D-ESKD in AAs. Genetic studies have revealed >70 genome-wide significant of genetic determinants with impact on kidney diseases or kidney functions. Despite the progress, the proportion of T2D-ESKD susceptibility attributed by these kidney related genes is still unclear. The goal of this series of studies is to provide a comprehensive evaluation of the genetic architecture of T2D-ESKD in AAs.","abstract_html":"End-stage kidney disease (ESKD) is a significant public health problem in the U.S., disproportionately affecting African Americans (AAs; 1,003 per million/year) at 3.3-fold higher incidence rate than European Americans (301 per million/year), and 2-fold higher than Native Americans (499 per million/year) in 2014. Diabetic kidney disease (DKD), primarily attributed to type 2 diabetes (T2D), including ESKD and advanced chronic kidney disease (CKD) accounts for over 40% of all ESKD cases. Observation of familial aggregation in epidemiologic studies suggests that genetic factors may contribute to the risk of DKD. While apolipoprotein L1 gene (APOL1) G1 and G2 alleles explain approximately 70% of the disparity in non-diabetic ESKD in AAs, they fail to account for the excess risk of T2D-ESKD in AAs. Genetic studies have revealed >70 genome-wide significant of genetic determinants with impact on kidney diseases or kidney functions. Despite the progress, the proportion of T2D-ESKD susceptibility attributed by these kidney related genes is still unclear. The goal of this series of studies is to provide a comprehensive evaluation of the genetic architecture of T2D-ESKD in AAs.","abstract_has_math":false,"creators":["Guan, Meijian"],"institution":"Wake Forest University","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2017,"date_issued":"2017","date_published":"2017","updated_at":"2026-07-27T22:02:17Z","subjects":["African Americans"],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/10339/86347","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["Guan, Meijian"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2017-08-22T08:35:25Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2019-08-21T08:30:13Z"]},{"key":"dc:date.issued","label":"Date","values":["2017"]},{"key":"dc:publisher","label":"Institution","values":["Wake Forest University"]},{"key":"dc:type","label":"Dc Type","values":["Dissertation"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["African Americans"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/10339/86347"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["End-stage kidney disease (ESKD) is a significant public health problem in the U.S., disproportionately affecting African Americans (AAs; 1,003 per million/year) at 3.3-fold higher incidence rate than European Americans (301 per million/year), and 2-fold higher than Native Americans (499 per million/year) in 2014. Diabetic kidney disease (DKD), primarily attributed to type 2 diabetes (T2D), including ESKD and advanced chronic kidney disease (CKD) accounts for over 40% of all ESKD cases. Observation of familial aggregation in epidemiologic studies suggests that genetic factors may contribute to the risk of DKD. While apolipoprotein L1 gene (APOL1) G1 and G2 alleles explain approximately 70% of the disparity in non-diabetic ESKD in AAs, they fail to account for the excess risk of T2D-ESKD in AAs. Genetic studies have revealed >70 genome-wide significant of genetic determinants with impact on kidney diseases or kidney functions. Despite the progress, the proportion of T2D-ESKD susceptibility attributed by these kidney related genes is still unclear. The goal of this series of studies is to provide a comprehensive evaluation of the genetic architecture of T2D-ESKD in AAs."]},{"key":"dc:title","label":"Title","values":["Evaluation of genetic variants for Type 2 diabetes associated kidney disease in African Americans"]}]}],"canonical_facts":{"dc:creator":["Guan, Meijian"],"dc:date.accessioned":["2017-08-22T08:35:25Z"],"dc:date.available":["2019-08-21T08:30:13Z"],"dc:date.issued":["2017"],"dc:description.abstract":["End-stage kidney disease (ESKD) is a significant public health problem in the U.S., disproportionately affecting African Americans (AAs; 1,003 per million/year) at 3.3-fold higher incidence rate than European Americans (301 per million/year), and 2-fold higher than Native Americans (499 per million/year) in 2014. Diabetic kidney disease (DKD), primarily attributed to type 2 diabetes (T2D), including ESKD and advanced chronic kidney disease (CKD) accounts for over 40% of all ESKD cases. Observation of familial aggregation in epidemiologic studies suggests that genetic factors may contribute to the risk of DKD. While apolipoprotein L1 gene (APOL1) G1 and G2 alleles explain approximately 70% of the disparity in non-diabetic ESKD in AAs, they fail to account for the excess risk of T2D-ESKD in AAs. Genetic studies have revealed >70 genome-wide significant of genetic determinants with impact on kidney diseases or kidney functions. Despite the progress, the proportion of T2D-ESKD susceptibility attributed by these kidney related genes is still unclear. The goal of this series of studies is to provide a comprehensive evaluation of the genetic architecture of T2D-ESKD in AAs."],"dc:identifier.uri":["http://hdl.handle.net/10339/86347"],"dc:language.iso":["en"],"dc:publisher":["Wake Forest University"],"dc:subject":["African Americans"],"dc:title":["Evaluation of genetic variants for Type 2 diabetes associated kidney disease in African Americans"],"dc:type":["Dissertation"]},"updated_at":"2026-07-27T22:02:17Z"}